Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - December 3, 2002
The purpose of the extended agreement is to test the combination of the two companies' leading edge technologies in an effort to develop a vaccine against HIV, the causative agent of AIDS. Based on the success of the previous studies, Chiron now plans to include more advanced studies in large animals as a prelude to possible future clinical development of a DNA vaccine for HIV. In addition to the studies covered by this Agreement, Genetronics and Chiron have a collaborative relationship, which explores electroporation assisted delivery of a second DNA vaccine for an unnamed target indication.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) indicates that in less than 20 years after HIV and AIDS were identified, AIDS has become the most important infectious disease, the first cause of death in Africa, and the fourth leading cause of death worldwide. More than 15,000 new HIV infections occur every day, most of them in developing countries, and over 33 million people now live with HIV or AIDS.
About Genetronics
Genetronics Inc. is the world leader in electroporation therapy with 216 patents issued, allowed, or pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic genes or vaccines using electroporation. More information can be obtained at http://www.genetronics.com .
This press release contains certain forward-looking statements relating to the Company's plans to develop its electroporation drug and gene delivery technology, potential partnerships and to maximize shareholder value. Actual events or results may differ from the Company's expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of the Company's technology and applications by potential partners, and capital market conditions, and others set forth in the Genetronics Annual Report, on Form 10-K and other regulatory filings. There can be no assurance that any product in the Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market products. The American and Toronto Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.
SOURCE Genetronics Inc.
Web Site: http://www.genetronics.com
021203
PR021204
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .